MedDataX Logo

Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

NCT ID: NCT00348686

Last Updated: 2012-04-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

315 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

NCT01135212

Hypertension
COMPLETED PHASE3

Candesartan Effect in Second Stage Arterial Hypertension

NCT00621153

Stage II Hypertension
COMPLETED PHASE4

Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension

NCT01152567

Hypertension Cardiovascular Disease
COMPLETED

Evaluation of Atacand® (Candesartan) in Daily Medical Practice

NCT00837720

Hypertension
COMPLETED

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

NCT00634400

Congestive Heart Failure
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Left Ventricular Hypertrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Candesartan

Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.

Group Type EXPERIMENTAL

Candesartan

Intervention Type DRUG

16 mg once daily in oral tablet form

Candesartan

Intervention Type DRUG

32 mg once daily in oral tablet form

Felodipine

Intervention Type DRUG

5 mg once daily in oral tablet form

Felodipine

Intervention Type DRUG

10 mg once daily in oral tablet form

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Candesartan

16 mg once daily in oral tablet form

Intervention Type DRUG

Candesartan

32 mg once daily in oral tablet form

Intervention Type DRUG

Felodipine

5 mg once daily in oral tablet form

Intervention Type DRUG

Felodipine

10 mg once daily in oral tablet form

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Atacand Antacand

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypertension with diastolic blood pressure within 95-115 mm/Hg or/and systolic blood pressure within 160-200 mm/Hg
* Patients diagnosed as left ventricular hypertrophy by electrocardiogram

Exclusion Criteria

* Secondary hypertension
* History of myocardial infarction
* Stroke within the previous 6 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

JeeWoong Son, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Busan, , South Korea

Site Status

Research Site

Cheonan, , South Korea

Site Status

Research Site

Cheongju-si, , South Korea

Site Status

Research Site

Chunbuk, , South Korea

Site Status

Research Site

Daegu, , South Korea

Site Status

Research Site

Daejeon, , South Korea

Site Status

Research Site

Gyungsangnamdo, , South Korea

Site Status

Research Site

Jeonju, , South Korea

Site Status

Research Site

Kwangju, , South Korea

Site Status

Research Site

Pusan, , South Korea

Site Status

Research Site

Ulsan, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAP

Identifier Type: -

Identifier Source: secondary_id

D2452L00012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
NCT02368652 COMPLETED PHASE3
A Pharmacogenomic Study of Candesartan in Heart Failure
NCT00400582 COMPLETED PHASE4
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy
NCT02368665 COMPLETED PHASE3
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
NCT00434967 COMPLETED PHASE3
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
NCT00383929 COMPLETED PHASE3
A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
NCT02059616 UNKNOWN PHASE2
Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France
NCT00679640 COMPLETED
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
NCT00607633 COMPLETED
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
NCT00775814 COMPLETED PHASE4
MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
NCT02177396 COMPLETED PHASE3
Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient(Kanarb-Hypertension Epidemiology Medication Satisfaction Study)
NCT02394392 COMPLETED
Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)
NCT01025843 COMPLETED PHASE1
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
NCT02521233 WITHDRAWN PHASE3
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
NCT01289132 COMPLETED PHASE2
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
NCT02211638 COMPLETED
Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG
NCT03219632 COMPLETED
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
NCT00242346 COMPLETED PHASE3
Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
NCT01928628 COMPLETED PHASE3
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
NCT00902304 COMPLETED PHASE4
Scandinavian Candesartan Acute Stroke Trial (SCAST)
NCT00120003 COMPLETED PHASE3
Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo
NCT00282178 COMPLETED PHASE2
Atacand (Candesartan) Real Life Study
NCT00620178 COMPLETED
CKD-330 Drug-Drug Interaction Study (Candesartan)
NCT02064621 COMPLETED PHASE1
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
NCT06643819 RECRUITING PHASE3
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
NCT01681576 COMPLETED PHASE2